IncontiLase

What is IncontiLase®?

IncontiLase® is a innovative and unique, patent-pending, non-invasive Er:YAG laser therapy for incontinence. It is based on non-ablative photothermal tension and shrinkage of the urethral and anterior bladder wall region. The indications for IncontiLase® therapy are mild and moderate stress and mixed urinary incontinence (SUI). Preliminary clinical studies show that it is an efficient, easyto-perform and safe procedure.

How does IncontiLase® work?

The IncontiLase® treatment is based on precisely controlled laser-induced thermal effects in the mucosa tissue in the region of the vestibule and urethral orifice, as well as in the area along the anterior vaginal wall.

The laser used in IntimaLase clinical trials is a 2940 nm Er:YAG, with builtin proprietary technology solutions that enable delivery of specially composed laser energy packages to the vaginal mucosa tissue and to collagen-rich endopelvic fascia.

Studies have shown that the resulting collagen neogenesis and remodeling leads to the shrinking and tightening of irradiated tissues, and the return of normal continence function.

Unique advantages of IntcontiLase® for your patients

For a large majority of patients included in the study, a single session was sufficient to alleviate mild or even moderate stress urinary incontinence. If needed, the treatment was repeated after one month. No special pre-op preparations or postop precautions were necessary. Patients could immediately return to their normal everyday activities. Additional advantages of IncontiLase® are that the procedure is incisionless and virtually painless, with no ablation, cutting, bleeding, or sutures. Recovery is extremely quick without need for the use of analgesics or antibiotics.

Promising clinical results

The latest IncontiLase® scientific results, presented by LA&HA specialists Dr. Riviera and Dr. Fistonić, show excellent improvement for mild and moderate stress urinary incontinence. Assessments of efficacy were based on subjective patients’ evaluations through standardized questionnaires as well as objective Q-tip and PFM measurements. 90% of patients with mild SUI and 76% of patients with moderate SUI needed just a single IncontiLase® treatment. In total, 95% of all patients were incontinence free 12 months after the treatment, while 5% still had mild stress incontinence.